RT @ericdeinmd: #EULAR2022 LB0006 SAPHYR: P3 trial, 52 wk: Sarilumab in relapsing PMR Study terminated early due to COVI
Tweet Content
#EULAR2022 LB0006
SAPHYR: P3 trial, 52 wk: Sarilumab in relapsing PMR
Study terminated early due to COVID recruitment
⭐️Sustained remission: 28 vs 10%, primary endpt
⭐️HR of flare 0.56 on Sarilumab
⭐️Less steroid usage, glucocorticoid tox score
@Rheumnow https://t.co/5PP1YP7YtU
Show on Archive Page
On
Display in Search Results
On
PDQ
Off